Will Patient-Reported Data Require New Drug Labeling Framework?
Whether US FDA may need to create a special labeling section for patient experience data is a ‘huge question that’s going to require a lot of discussion,’ Oncology Center of Excellence’s Kluetz says; agency is currently exploring non-labeling alternatives to communicating PRO data.
You may also be interested in...
Patient-Reported Outcomes In Pediatric Cancer Trials Endorsed By US FDA Advisory Committee
Incorporation of the Ped-PRO-CTCAE instrument would help inform short-term tolerability and long-term effects of treatment, particularly newer immunotherapy agents, but there are logistical and operational challenges to overcome, advisory committee members said.
From Listening To Advising: The Maturation Of US FDA's Patient-Focused Drug Development Program
With the disease-area meetings required under PDUFA V now behind it, FDA is turning its attention to guiding sponsors and advocacy groups on how to systematically collect patient experience data for use in drug development and regulatory decision-making. At least two guidance documents and a new data repository are on tap for 2018.
Patient Experience Data May Require Separate Label, Genentech Suggests
US labeling for Genentech's Rituxan Hycela appears to have broken new ground with a 'Patient Experience' section describing summary data from a patient preference study; however, the company's global head of outcomes research says large volumes of patient-centric data would be difficult to reflect within the current labeling framework.